Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan-Reference-Cited by-同舟云学术

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan

Published:2019-04-26 Issue:8 Volume:49 Page:766-771
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Kosaka Takeo¹,Uemura Hiroji²,Sumitomo Makoto³,Harada Kenichi⁴,Sugimoto Mikio⁵,Hayashi Narihiko⁶,Yoshimura Kazuhiro⁷,Fukasawa Satoshi⁸,Ecstein-Fraisse Evelyne⁹,Sunaga Yoshinori¹⁰,Oya Mototsugu¹

Affiliation:

1. Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

2. Department of Urology/Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama 232-0024, Japan

3. Department of Urology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan

4. Department of Urology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan

5. Department of Urology, Kagawa University Hospital, 1750-1 Ikenobe, Miki Kita-gun, Kagawa 761-0793, Japan

6. Department of Urology, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan

7. Department of Urology, Kindai University Hospital, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan

8. Department of Urology/Prostate Cancer, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba 260-0801, Japan

9. Medical Evidence Generation, Sanofi, 54 rue La Boétie, Paris 75008, France

10. Biostatistics Programming, Oncology, Sanofi, 640 Memorial Drive, Cambridge MA 02142, USA

Abstract

Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduced incidence of febrile neutropenia in Japanese metastatic castration-resistant prostate cancer patients. Cabazitaxel+G-CSF therapy was a safe and effective treatment option.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/49/8/766/31773740/hyz051.pdf

Reference23 articles.

1. Preclinical evaluation of TXD258, a new taxoid;Bissery;Proc Am Assoc Cancer Res,2000

2. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines;Aller;Proc Am Assoc Cancer Res,2000

3. Preclinical evaluation of new taxoids;Bissery;Curr Pharm Des,2001

4. Cabazitaxel, a new taxane with favorable properties;Bouchet;Drugs Today,2010

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022;International Journal of Clinical Oncology;2024-03-28

2. The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2023-09-29

3. Factors associated with thrombocytopenia in patients treated with pegfilgrastim;Int. Journal of Clinical Pharmacology and Therapeutics;2023-06-01

4. Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel;Supportive Care in Cancer;2023-05

5. Incidence and predictors of febrile neutropenia in patients with metastatic castrate- resistant prostate cancer receiving docetaxel;2022-11-21